Curative Biotechnology, Inc. (CUBT)

0.0150 +0.0030 (+25.00%) At close: 01:42PM EDT

Curative Biotechnology, Inc.

3801 PGA Blvd
Suite 600
Palm Beach Gardens, FL 33410
United States
561 907 8990
https://curativebiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 4

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul M. Michaels	President & Executive Chairman	783.11k	N/A	1967
Mr. I. Richard Garr Esq., J.D.	CEO, CFO, Principal Accounting Officer & General Counsel	438k	N/A	1953
Mr. Pam Bisikirski	Vice President of Communications	N/A	N/A	N/A
Dr. Ronald Bordens Ph.D.	Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory Board	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.

Corporate governance

Curative Biotechnology, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.